Equity Overview
Price & Market Data
Price: $14.94
Daily Change: +$0.55 / 3.68%
Range: $14.02 - $14.96
Market Cap: $771,136,576
Volume: 1,057,937
Performance Metrics
1 Week: 51.86%
1 Month: -0.70%
3 Months: -9.92%
6 Months: 116.1%
1 Year: 195.9%
YTD: -19.25%
Company Details
Employees: 209
Sector: Health technology
Industry: Biotechnology
Country: Netherlands
Details
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.